Trial · NCT00064077
Adverse events424
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 424
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Leukopenia | Blood and lymphatic system disorders | Arm I (Paclitaxel, Cisplatin) | 92 | 103 | |
| other | Leukopenia | Blood and lymphatic system disorders | Arm II (Vinorelbine, Cisplatin) | 98 | 108 | |
| other | Leukopenia | Blood and lymphatic system disorders | Arm III (Gemcitabine, Cisplatin) | 90 | 112 | |
| other | Leukopenia | Blood and lymphatic system disorders | Arm IV (Topotecan, Cisplatin) | 102 | 111 | |
| other | Anemia | Blood and lymphatic system disorders | Arm I (Paclitaxel, Cisplatin) | 94 | 103 | |
| other | Anemia | Blood and lymphatic system disorders | Arm II (Vinorelbine, Cisplatin) | 100 | 108 | |
| other | Anemia | Blood and lymphatic system disorders | Arm III (Gemcitabine, Cisplatin) | 104 | 112 | |
| other | Anemia | Blood and lymphatic system disorders | Arm IV (Topotecan, Cisplatin) | 106 | 111 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Arm I (Paclitaxel, Cisplatin) | 36 | 103 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Arm II (Vinorelbine, Cisplatin) | 32 | 108 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Arm III (Gemcitabine, Cisplatin) | 88 | 112 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Arm IV (Topotecan, Cisplatin) | 87 | 111 | |
| other | Neutropenia | Blood and lymphatic system disorders | Arm I (Paclitaxel, Cisplatin) | 92 | 103 | |
| other | Neutropenia | Blood and lymphatic system disorders | Arm II (Vinorelbine, Cisplatin) | 94 | 108 | |
| other | Neutropenia | Blood and lymphatic system disorders | Arm III (Gemcitabine, Cisplatin) | 76 | 112 | |
| other | Neutropenia | Blood and lymphatic system disorders | Arm IV (Topotecan, Cisplatin) | 102 | 111 | |
| other | Otherhematologic | Blood and lymphatic system disorders | Arm I (Paclitaxel, Cisplatin) | 38 | 103 | |
| other | Otherhematologic | Blood and lymphatic system disorders | Arm II (Vinorelbine, Cisplatin) | 53 | 108 | |
| other | Otherhematologic | Blood and lymphatic system disorders | Arm III (Gemcitabine, Cisplatin) | 57 | 112 | |
| other | Otherhematologic | Blood and lymphatic system disorders | Arm IV (Topotecan, Cisplatin) | 57 | 111 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00064077/events